Status:
UNKNOWN
The Significance of Circulating Microvesicles in Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Pulmonary Hypertension Due to Chronic
Obstructive Pulmonary Disease
Eligibility:
All Genders
18+ years
Brief Summary
Mild to moderate pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD); such a complication is associated with increased risks of exacerbation and decreased s...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age ≥ 18
- COPD: obstructive ventilatory insufficient on spirometry and history of smoking
- patients who will perform right heart catheterization
- Signature of written informed consent
- Exclusion criteria:
- LVEF \< 45% (echocardiography)
- Post-capillary pulmonary hypertension (pulmonary capillary wedge pressure \> 15 mmHg)
- Chronic Thromboembolic hypertension
- Pulmonary embolism \< 6 months
- Acute coronary syndrome \< 3 months
- Significant cardiac valvulopathy (echocardiography)
- Portal hypertension
- Connective tissue disease
- chronic renal insufficient (clearance \< 40 ml/min)
- Glycated hemoglobin \> 7% (if diabetes)
- Non controlled arterial hypertension
- Positive beta-HCG
- Respiratory exacerbation during the inclusive period
- Patients under guardianship or curatorship
Exclusion
Key Trial Info
Start Date :
September 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05250128
Start Date
September 1 2022
End Date
September 1 2025
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpitaux Universitaire de Strasbourg - Service Pneumologie - centre de compétence de l'hypertension artérielle pulmonaire - France
Strasbourg, France, 67091